GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

Current xenogeneic mouse models cannot evaluate on-target off-tumor adverse effect, hindering the development of chimeric antigen receptor (CAR) T cell therapies for solid tumors, due to limited human/mouse cross-reactivity of antibodies used in CAR and sever graft-versus-host disease induced by adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Daiki, Yaguchi, Tomonori, Iwata, Takashi, Katoh, Yuki, Morii, Kenji, Tsubota, Kinya, Takise, Yoshiaki, Tamiya, Masaki, Kamada, Haruhiko, Akiba, Hiroki, Tsumoto, Kouhei, Serada, Satoshi, Naka, Tetsuji, Nishimura, Ryohei, Nakagawa, Takayuki, Kawakami, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108862/
https://www.ncbi.nlm.nih.gov/pubmed/32228854
http://dx.doi.org/10.7554/eLife.49392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108862/
https://www.ncbi.nlm.nih.gov/pubmed/32228854
http://dx.doi.org/10.7554/eLife.49392

Ejemplares similares